France· FR:63869763
WELIREG 40 mg, comprimé pelliculé
A belzutifan product containing belzutifan, registered in France by MERCK SHARP & DOHME (PAYS-BAS), on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
Where it is registered
Belzutifan is registered in 14 of 19 countries.
Countries holding a registration under ATC L01XX74 (belzutifan), each read from that country’s own register.
- This record: France, from Base de données publique des médicaments — BDPM (France)
- 8 of them publish a price we can compare per daily dose
Belzutifan · ATC L01XX74
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of belzutifan costs, country by country.
Normalised to the WHO defined daily dose (0.12 g), so markets compare like for like.
- France: $0.54 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Belzutifan · price per daily dose (0.12 g)
USD · FX 28 Sept 2026
- FR France$0.54
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- BELZUTIFAN
- Manufacturer
- MERCK SHARP & DOHME (PAYS-BAS)
- Country
- France (FR)
- ATC code
- L01XX74
- ATC class
- Belzutifan
- Defined daily dose
- 0.12 g, O
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cip133400930309032plaquettes aluminium de 90 (3 x 30) comprimés, (conditionnement multiple)EUR 14.18
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Belzutifan in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwitzerlandWelireg 40 mg, FilmtablettenMSD Merck Sharp & Dohme AG
- United StatesWELIREGMerck Sharp & Dohme LLC
- SpainWELIREG 40 MG COMPRIMIDOS RECUBIERTOS CON PELICULAMerck Sharp & Dohme B.V.
- FinlandWELIREGMerck Sharp & Dohme B.V.
- BelgiumWelireg 40 mgMerck Sharp & Dohme
- IcelandWeliregMerck Sharp & Dohme B.V.*
- NetherlandsWELIREG 40 mg filmomhulde tablettenMerck Sharp & Dohme B.V.
- PolandWeliregMerck Sharp & Dohme B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Welireg
- Liechtenstein · Welireg
- Norway · Welireg
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/6ea8d6f7-ebf5-47fd-a2aa-16023755419f GET /v1/drugs/6ea8d6f7-ebf5-47fd-a2aa-16023755419f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "63869763",
"date_amm": "2025-02-12",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/24/1893",
"substance": "BELZUTIFAN",
"atc_source": "fr_atc_restore_2026-09-06",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "comprimé pelliculé",
"voies_administration": "orale",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Oui"
}See everything about belzutifan.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.